When EGFR-TKI-ICB combination treatment was used instead of pembrolizumab or gefitinib monotherapy, NSCLC patients showed improved clinical benefit, with increased overall response rate (41.7% versus 14.3%) and median progression-free survival (19.5 months versus 1.4 months) (582). Here, EGFR is linked to non-small cell lung carcinoma.